Semaglutide vs Tirzepatide for Weight Loss: An Honest Comparison

Semaglutide vs tirzepatide: the short, honest answer

If you want the quick version: both are prescription medications that may support weight management for some people, when a licensed clinician decides they are appropriate. The main difference is how many hormone pathways each one works on. Semaglutide acts on one. Tirzepatide acts on two.

In head-to-head research on the FDA-approved brand medications (not the compounded versions), tirzepatide produced somewhat greater average weight reduction than semaglutide, though an average never predicts any one person's result. "Average" is not a promise, and it may not describe you. The better medication is the one that fits your health history, that you tolerate, and that a clinician judges to be a reasonable option. Neither is a shortcut, and neither works for everyone.

How each one works: GLP-1 alone vs dual GIP/GLP-1 action

Both medications imitate hormones your gut releases after you eat.

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone that helps signal fullness, slows how quickly your stomach empties, and supports blood-sugar regulation. For many people, that adds up to feeling satisfied sooner and staying full longer, which can make eating less feel less like a constant fight.

Tirzepatide works on two receptors at once: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP is a second gut hormone involved in how your body handles sugar and fat. The idea behind "dual agonism" is that engaging both pathways may have a larger combined effect on appetite and metabolism than GLP-1 alone. Whether that translates into a meaningful difference for any one person still varies.

TelePep's Microdose GLP-1 program uses compounded semaglutide or compounded tirzepatide, always after a clinician review. More on what "compounded" means below.

What head-to-head research actually shows (ranges, not promises, and why results vary)

Here is where honesty matters most.

The brand-name versions of these medications have been studied in large clinical trials, and one trial compared them directly. In the first published head-to-head trial (SURMOUNT-5, 72 weeks), participants on tirzepatide lost more weight on average than those on semaglutide — roughly 20% of body weight at higher tirzepatide doses versus about 14% for semaglutide. Those are trial averages from the FDA-approved brand products, at specific doses, paired with lifestyle changes and clinical supervision — not a promise for any individual.

These figures come from trials of FDA-approved brand medications, not from compounded semaglutide or tirzepatide. There is no clinical-trial data on how much weight the compounded versions used in TelePep's Microdose GLP-1 program help people lose, and no one can predict an individual result.

A few caveats any careful clinician would add:

• These were averages. Some people lost much more, some much less, and some did not respond well at all.
• The trials studied FDA-approved brand medications, not compounded versions.
• Results depend heavily on dose, how long you stay on treatment, diet, activity, sleep, and other health factors.
• Weight often returns after stopping, which is why these are generally viewed as long-term tools rather than quick fixes.

Just as important: these weight-loss figures come from trials of the FDA-approved brand medications. Compounded semaglutide and compounded tirzepatide have not been studied in these head-to-head trials, and there is no guarantee a compounded version will produce the same results. TelePep's Microdose GLP-1 program uses compounded medication, so treat these brand-trial numbers as background, not a promise of what you would experience.

So tirzepatide having a higher average does not mean it is automatically "better" for you. Tolerance, cost, health history, and clinician judgment all matter.

Side effects, and who should not take either medication

Both medications share a similar side-effect profile, and the risks are real.

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These tend to show up most when starting or increasing a dose, and they ease for many people over time, though not for everyone. Clinicians usually start low and increase slowly to reduce this.

Less common but more serious risks can include pancreatitis, gallbladder problems, dehydration, and low blood sugar (especially when combined with certain diabetes medications). Both carry a boxed warning, based on rodent studies, about a rare type of thyroid tumor. The human risk is not established, but it shapes who should avoid them.

You should not take either medication if you:

• Are pregnant, breastfeeding, or trying to become pregnant.
• Have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Have had a serious allergic reaction to semaglutide, tirzepatide, or their ingredients.

Use extra caution, and tell your clinician, if you have a history of pancreatitis, gallbladder disease, severe gastrointestinal conditions, diabetic eye disease, or kidney problems. Always share every medication and supplement you take. This is exactly the kind of screening a visit is for.

Compounded vs brand: what "not FDA-approved" really means here

This is important and often glossed over, so we will say it plainly.

The brand-name versions of semaglutide and tirzepatide are FDA-approved. Compounded semaglutide and compounded tirzepatide are not FDA-approved. Compounded medications are prepared by licensed compounding pharmacies for an individual patient, and they do not go through the same FDA approval and manufacturing-review process that brand drugs do.

That is not a hidden asterisk; it is a real distinction you deserve to weigh. Compounding is a long-standing, regulated part of US pharmacy, but "not FDA-approved" means the specific compounded product has not been evaluated by the FDA for safety, effectiveness, or quality the way an approved drug has.

Because the compounded versions have not been through FDA trials, we cannot cite an expected weight-loss figure for them; any outcome depends on the individual and on clinician judgment. The trial numbers above describe brand products, not the compounded medication in our program.

TelePep's Microdose GLP-1 program uses compounded semaglutide or tirzepatide. We think patients should understand that trade-off before starting, and a clinician will discuss it with you.

Cost, compared plainly (TelePep: $149/mo, or $134/mo annual, $0 today)

Cost is often the deciding factor, so here is ours without spin.

TelePep's Microdose GLP-1 program is $149 per month, or $134 per month on an annual plan. You pay $0 today. You are charged only if a licensed clinician reviews your visit and prescribes. If it is not appropriate for you, you do not pay for medication.

Brand-name GLP-1 medications can cost far more out of pocket without insurance coverage, and coverage varies a great deal from plan to plan. We are not going to quote a brand price war here, because what you would actually pay depends on your insurance and pharmacy. The honest point is simply that direct-pay pricing is predictable, and you are not committing money before a clinician weighs in.

How a licensed clinician decides which may be appropriate for you

There is no formula that spits out one answer. A clinician looks at the whole picture, which typically includes:

• Your health history, and any conditions that would make one medication safer than the other, or rule both out.
• Every medication and supplement you currently take.
• Your goals, and whether medication is a reasonable tool alongside diet, activity, and sleep.
• How you have tolerated similar medications before, if at all.
• Practical factors like cost and availability.

Sometimes the answer is one medication, sometimes the other, and sometimes it is "not right now" or "not this route." A responsible clinician is willing to say no when that is the honest call.

Common questions: switching, dosing cadence, and availability in your state

Can I switch from one to the other? Sometimes. People switch for reasons of tolerance, response, cost, or availability, but it should be a clinical decision, not a do-it-yourself one. Your clinician will guide dosing if a switch makes sense.

How often would I take it? Both semaglutide and tirzepatide are typically given as a once-weekly injection, usually starting at a low dose that is increased gradually. Your exact plan is set by the prescribing clinician.

How much weight will I lose on the compounded version? No one can tell you that honestly. The weight-loss figures from clinical trials come from the FDA-approved brand medications, not the compounded semaglutide or tirzepatide used in our program, and there is no head-to-head trial data for the compounded versions. Any result depends on the individual, the dose, lifestyle factors, and clinician judgment. Treat the brand-trial averages as background, not a prediction for you.

Will the weight stay off? Often, weight tends to return after stopping, which is why these are generally used as longer-term tools with lifestyle support rather than a short course. There are no guarantees, and results vary from person to person.

Is it available in my state? TelePep serves 48 US states plus Washington, DC. We are not available in Alaska or Mississippi. If you are elsewhere in the US, you can start a visit.

Starting a visit: what happens, and why you pay nothing unless prescribed

If you are curious whether this route fits you, you can start a visit. You share your health history, a licensed clinician reviews everything, and, if appropriate, they may prescribe a compounded GLP-1 option through the Microdose GLP-1 program. If it is not a fit, they will tell you, and you will not be charged for medication.

Ready when you are: start a visit and a licensed clinician reviews everything, $0 unless prescribed. A real person reads this inbox, so if you have questions before starting, just ask.